Key Points
- Arturo Md Molina sold 13,151 shares on Jan. 23 at an average of $82.42 for $1,083,905.42 and has sold a total of 18,151 shares across recent trades, reducing his ownership to 84,115 shares (a 13.52% decrease).
- Other senior insiders also sold heavily: CEO Dinesh V. Patel sold 48,273 shares (~$4.06M) and CFO Asif Ali sold 46,203 shares (~$3.84M), actions the article notes could be perceived negatively by the market.
- Protagonist shares trade around $83 (52-week range $33.70–$96.54) with a market cap of about $5.19B, and analysts hold a consensus "Moderate Buy" rating with a target of $86.77.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) CEO Dinesh Ph Patel sold 4,068 shares of the firm's stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $83.19, for a total transaction of $338,416.92. Following the completion of the sale, the chief executive officer owned 574,505 shares of the company's stock, valued at $47,793,070.95. This trade represents a 0.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Protagonist Therapeutics Stock Up 0.9%
Shares of NASDAQ PTGX opened at $83.08 on Wednesday. The business's 50 day moving average price is $86.49 and its two-hundred day moving average price is $72.41. The company has a market cap of $5.19 billion, a PE ratio of 134.00 and a beta of 2.26. Protagonist Therapeutics, Inc. has a twelve month low of $33.70 and a twelve month high of $96.54.
Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.03). Protagonist Therapeutics had a net margin of 21.94% and a return on equity of 6.86%. The business had revenue of $4.71 million during the quarter, compared to analyst estimates of $5.41 million. As a group, research analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.
Analysts Set New Price Targets
Several brokerages have recently weighed in on PTGX. Johnson Rice set a $112.00 price objective on shares of Protagonist Therapeutics in a research report on Monday, October 13th. Citizens Jmp increased their price target on shares of Protagonist Therapeutics from $69.00 to $102.00 and gave the company a "market outperform" rating in a report on Friday, November 7th. JPMorgan Chase & Co. raised their price objective on shares of Protagonist Therapeutics from $68.00 to $81.00 and gave the stock an "overweight" rating in a research report on Friday, November 7th. BTIG Research restated a "buy" rating and set a $82.00 price objective on shares of Protagonist Therapeutics in a report on Tuesday, October 28th. Finally, Weiss Ratings upgraded Protagonist Therapeutics from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday, December 24th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Protagonist Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $86.77.
View Our Latest Research Report on PTGX
Institutional Investors Weigh In On Protagonist Therapeutics
Institutional investors have recently made changes to their positions in the stock. Farther Finance Advisors LLC grew its position in Protagonist Therapeutics by 110.6% during the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company's stock worth $26,000 after buying an additional 156 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in shares of Protagonist Therapeutics during the 2nd quarter valued at $27,000. Bessemer Group Inc. grew its holdings in shares of Protagonist Therapeutics by 171.0% during the 2nd quarter. Bessemer Group Inc. now owns 504 shares of the company's stock worth $28,000 after purchasing an additional 318 shares in the last quarter. Salomon & Ludwin LLC bought a new position in shares of Protagonist Therapeutics in the third quarter worth $29,000. Finally, CWM LLC raised its stake in Protagonist Therapeutics by 201.5% in the second quarter. CWM LLC now owns 609 shares of the company's stock valued at $34,000 after purchasing an additional 407 shares in the last quarter. 98.63% of the stock is currently owned by institutional investors.
More Protagonist Therapeutics News
Here are the key news stories impacting Protagonist Therapeutics this week:
- Negative Sentiment: CEO Dinesh V. Patel sold a total of 48,273 shares across three transactions (Jan. 23, Jan. 26 and Jan. 27) at prices between ~$83.19–$84.59, totaling roughly $4.06M. He still holds 574,505 shares. Large, repeated CEO sales may signal diversification or cashing-out at recent price levels and can be perceived negatively by the market. CEO filings
- Negative Sentiment: CFO Asif Ali sold 46,203 shares on Jan. 27 at an average price of $83.13 for about $3.84M, reducing his stake by ~43% to 60,320 shares. A CFO trimming nearly half of his position is a more notable red flag for investors because of the officer’s financial perspective and the size of the reduction. CFO filing
- Negative Sentiment: Insider Arturo Md Molina sold 13,151 shares on Jan. 23 (avg $82.42) and 5,000 shares on Jan. 27 (avg $82.00), totaling 18,151 shares and roughly $1.49M in proceeds; he retains 84,115 shares. Multiple insider sales by senior executives and directors can collectively amplify negative market perception. Insider filings
About Protagonist Therapeutics
(
Get Free Report)
Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist's approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.
Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn's disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
